A clinical and economic comparison of roxithromycin 150 mg twice daily vs amoxicillin 500mg/calvulanic acid 125mg three times daily for the treatment of lower respiratory tract infections in general practice

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The authors concluded that roxithromycin appeared to be a more appropriate choice than amoxicillin/clavulanic acid for the treatment of LRTI, given the more appropriate in vitro spectrum, the efficacy against all common pathogens, greater cost-effectiveness, the more convenient dosage regimen and better tolerance.